NDAINTRAVENOUSSOLUTION
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM GA 68 EDOTREOTIDE (edotreotide gallium ga-68) by Imagin Medical is 68 dotatoc binds to somatostatin receptors, with highest affinity (k i = 2. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Gallium GA-68 Edotreotide is a PET imaging agent that binds to somatostatin receptors, particularly subtype 2 (sstr2), which are overexpressed on neuroendocrine tumor cells. It uses Gallium-68, a positron-emitting radionuclide, to enable PET imaging detection of somatostatin receptor-positive tumors. This diagnostic agent helps clinicians localize and stage neuroendocrine malignancies.
PeakPost-LOE
Product is at peak lifecycle stage with moderate competitive pressure (30), indicating mature commercialization phase with established market presence.
Mechanism of Action
68 DOTATOC binds to somatostatin receptors, with highest affinity (K i = 2.5± 0.5 nanomolar) for subtype 2 receptors (sstr2). Ga 68 DOTATOC binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress sstr2 receptors. Gallium 68 is a β+ emitting…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Gallium GA-68 Edotreotide positions professionals in the specialized diagnostic imaging space with exposure to nuclear medicine, oncology, and healthcare technology. Career trajectory is influenced by proximity to 2026 LOE and transition from growth to mature/declining phase, requiring strategic pivot toward lifecycle extension or adjacent market expansion.
Nuclear Medicine Specialist
Worked on GALLIUM GA 68 EDOTREOTIDE at Imagin Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.